Baseline characteristics for all patients
| Baseline characteristics, N = 582 (%) . | |
|---|---|
| CAR T-cell product | |
| Axi-cel | 360 (61.9) |
| Tisa-cel | 152 (26.1) |
| Liso-cel | 70 (12.0) |
| EBER positive | 17 |
| HIV positive∗ | 4 |
| Autoimmune disease | |
| Rheumatoid arthritis | 6 |
| SLE | 4 |
| Crohn disease | 4 |
| Sjogren syndrome | 1 |
| Ulcerative colitis | 1 |
| Psoriatic arthritis | 1 |
| Other | 9 |
| Median prior lines of therapy (range) | 3 (1-18) |
| Prior stem cell transplantation | |
| Autologous | 224 (38.5) |
| Allogeneic | 6 (1.0) |
| Best response to therapy | |
| CR | 261 (44.8) |
| PR | 103 (17.7) |
| SD | 50 (8.9) |
| PD | 94 (16.2) |
| NE | 12 (2.1) |
| Baseline characteristics, N = 582 (%) . | |
|---|---|
| CAR T-cell product | |
| Axi-cel | 360 (61.9) |
| Tisa-cel | 152 (26.1) |
| Liso-cel | 70 (12.0) |
| EBER positive | 17 |
| HIV positive∗ | 4 |
| Autoimmune disease | |
| Rheumatoid arthritis | 6 |
| SLE | 4 |
| Crohn disease | 4 |
| Sjogren syndrome | 1 |
| Ulcerative colitis | 1 |
| Psoriatic arthritis | 1 |
| Other | 9 |
| Median prior lines of therapy (range) | 3 (1-18) |
| Prior stem cell transplantation | |
| Autologous | 224 (38.5) |
| Allogeneic | 6 (1.0) |
| Best response to therapy | |
| CR | 261 (44.8) |
| PR | 103 (17.7) |
| SD | 50 (8.9) |
| PD | 94 (16.2) |
| NE | 12 (2.1) |
CR, complete response; EBER, Epstein-Barr virus–encoded RNA; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; SLE, systemic lupus erythematosus.
As reported per institutional policy.